Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1791-1798

  Yan, Zejun ^a,b   Jiang, Junhui ^b   Li, Fan ^c   Yang, Weiming ^c   Xie, Guohai ^b   Zhou, Cheng ^b   Xia, Shujie ^a   Cheng, Yue ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b NINGBO UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; EGFR; LRIG1

Indexed keywords

ADENOVIRUS VECTOR; CISPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN LRIG1; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS PROTEIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; LRIG1 PROTEIN, HUMAN; MEMBRANE PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATADENOVIRUS; BLADDER CANCER; BLADDER CANCER CELL LINE; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG POTENTIATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LRIG1 GENE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; VIRUS GENE; ADENOVIRIDAE; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE; URINARY BLADDER NEOPLASMS;

ADENOVIRIDAE; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; HUMANS; MEMBRANE GLYCOPROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; URINARY BLADDER NEOPLASMS;

EID: 84924898329     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3807     Document Type: Article

References (34)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Herr HW, Dotan Z, Donat SM and Bajorin DF: Defining optimal therapy for muscle invasive bladder cancer. J Urol 177: 437-443, 2007.
3. Als AB, Sengelov L and von der Maase H: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies. Eur Urol 52: 478-486, 2007.
4. Basu A and Krishnamurthy S: Cellular responses to cisplatininduced DNA damage. J Nucleic Acids 2010: 201367, 2010.
5. Ciarimboli G: Membrane transporters as mediators of cisplatin side-effects. Anticancer Res 34: 547-550, 2014.
6. Li QQ, Wang G, Liang H, Li JM, Huang F, Agarwal PK, Zhong Y and Reed E: ?-Elemene promotes cisplatin-induced cell death in human bladder cancer and other carcinomas. Anticancer Res 33: 1421-1428, 2013.
7. Sekine I, Minna JD, Nishio K, Saijo N and Tamura T: Genes regulating the sensitivity of solid tumor cell lines to cytotoxic agents: a literature review. Jpn J Clin Oncol 37: 329-336, 2007.
8. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R and Hedman H: Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 284: 1155-1161, 2001.
9. Hedman H, Nilsson J, Guo D and Henriksson R: Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 41: 352-354, 2002.
10. Yang WM, Yan ZJ, Ye ZQ and Guo DS: LRIG1, a candidate tumour-suppressor gene in human bladder cancer cell line BIU87. BJU Int 98: 898-902, 2006.
11. Hedman H and Henriksson R: LRIG inhibitors of growth factor signalling-double-edged swords in human cancer? Eur J Cancer 43: 676-682, 2007.
12. Gur G, Rubin C, Katz M, et al: LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281, 2004.
13. Yarden Y: The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37: 3-8, 2001.
14. Pedersen MW, Melthorn M, Damstrup L and Poulsen HS: The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12: 745-760, 2001.
15. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A and Paradiso A: The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochim Biophys Acta 1766: 120-139, 2006.
16. Kim WT, Kim J, Yan C, et al: S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol 25: 974-979, 2014.
17. Hiraishi Y, Wada T, Nakatani K, Tojyo I, Matsumoto T, Kiga N, Negoro K and Fujita S: EGFR inhibitor enhances cisplatin sensitivity of oral squamous cell carcinoma cell lines. Pathol Oncol Res 14: 39-43, 2008.
18. Li F, Yang W, Guo D, Hu Z, Xu H and Ye Z: LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway. Oncol Rep 25: 1629-1637, 2011.
19. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
20. Ta HT, Dass CR, Larson I, Choong PF and Dunstan DE: A chitosan hydrogel delivery system for osteosarcoma gene therapy with pigment epithelium-derived factor combined with chemotherapy. Biomaterials 30: 4815-4823, 2009.
21. Zhang Y, Xing X, Zhan H, Li Q, Fan Y, Zhan L, Yu Q and Chen J: EGFR inhibitor enhances cisplatin sensitivity of human glioma cells. J Huazhong Univ Sci Technolog Med Sci 31: 773-778, 2011.
22. Yoshida T, Okamoto I, Iwasa T, Fukuoka M and Nakagawa K: The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. FEBS Lett 582: 4125-4130, 2008.
23. Geng X, Ye H, Feng Z, Lao X, Zhang L, Huang J and Wu ZR: Synthesis and characterization of cisplatin-loaded, EGFR?targeted biopolymer and in vitro evaluation for targeted delivery. J Biomed Mater Res A 100: 2839-2848, 2012.
24. Magkou C, Nakopoulou L, Zoubouli C, Karali K, Theohari I, Bakarakos P and Giannopoulou I: Expression of the epidermal growth factor receptor (EGFR) and the phosphorylated EGFR in invasive breast carcinomas. Breast Cancer Res 10: R49, 2008.
25. Tice DA, Biscardi JS, Nickles AL and Parsonss SJ: Mechanism of biological synergy between cellular Src and epidermal growth factor receptor. Proc Natl Acad Sci USA 96: 1415-1420, 1999.
26. Sheu JJ, Lee CC, Hua CH, et al: LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling. Oncogene 33: 1375-1384, 2014.
27. Suzuki Y, Miura H, Tanemura A, et al: Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett 521: 67-71, 2002.
28. Guo Z, Chen Q, Liu B, Tian D, Zhang S and Li M: LRIG1 enhances chemosensitivity by modulating BCL-2 expression and receptor tyrosine kinase signaling in glioma cells. Yonsei Med J 55: 1196-1205, 2014.
29. Williams GT and Smith CA: Molecular regulation of apoptosis: genetic controls on cell death. Cell 74: 777-779, 1993.
30. Nakashima T, Miura M and Hara M: Tetrocarcin A inhibits mitochondrial functions of Bcl-2 and suppresses its anti-apoptotic activity. Cancer Res 60: 1229-1235, 2000.
31. Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13: 1899-1911, 1999.
32. Adams JM and Cory S: The Bcl-2 apoptotic switch in cancer development and therapy Oncogene 26: 1324-1337, 2007.
33. Zhou W, Fu X Q, Liu J and Yu HG: RNAi knockdown of the Akt1 gene increases the chemosensitivity of gastric cancer cells to cisplatin both in vitro and in vivo. Regul Pept 176: 13-21, 2012.
34. Chen C, Zhou H, Xu L, Xu D, Wang Y, Zhang Y, Liu X, Liu Z, Ma D, Ma Q and Chen Y: Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo. Apoptosis 15: 805-813, 2010.